2021
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses
Shallis RM, Pollyea DA, Zeidan AM. The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses. Blood Reviews 2021, 48: 100806. PMID: 33531169, DOI: 10.1016/j.blre.2021.100806.Peer-Reviewed Original ResearchConceptsComplete remissionAcute myeloid leukemiaClinical benefitRate of CRMeasurable residual disease assessmentIncomplete platelet recoveryNon-intensive therapyPartial hematologic recoveryResidual disease assessmentFuture clinical trialsPost-therapy outcomesClinical responseHematologic recoveryOlder patientsComplete responseIntensive therapyStringent response criteriaPlatelet recoveryTherapeutic responseClinical trialsMyeloid leukemiaClinical valueNew therapiesMRD techniquesResponse criteria
2018
More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes
Shallis RM, Zeidan AM. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 2018, 18: 4. PMID: 29435332, PMCID: PMC5796398, DOI: 10.1186/s12878-018-0095-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHigh-risk myelodysplastic syndromeMyelodysplastic syndromeAcute myeloid leukemiaAdministration scheduleOverall survivalLower-risk myelodysplastic syndromesAlternative administration schedulesOutcomes of patientsAlternative dosing schedulesRisk of progressionMeaningful clinical responsesAgent azacitidineAZA-001Clinical responseConventional careDosing schedulesPeripheral cytopeniasProspective studyClinical trialsHematologic disordersMyeloid leukemiaMost trialsResponse ratePatientsSystematic review